| Home > Articles > Published articles > Development of Small Molecules Targeting α-Synuclein Aggregation : |
| Date: | 2023 |
| Abstract: | Parkinson's disease, the second most common neurodegenerative disorder worldwide, is characterized by the accumulation of protein deposits in the dopaminergic neurons. These deposits are primarily composed of aggregated forms of α-Synuclein (α-Syn). Despite the extensive research on this disease, only symptomatic treatments are currently available. However, in recent years, several compounds, mainly of an aromatic character, targeting α-Syn self-assembly and amyloid formation have been identified. These compounds, discovered by different approaches, are chemically diverse and exhibit a plethora of mechanisms of action. This work aims to provide a historical overview of the physiopathology and molecular aspects associated with Parkinson's disease and the current trends in small compound development to target α-Syn aggregation. Although these molecules are still under development, they constitute an important step toward discovering effective anti-aggregational therapies for Parkinson's disease. |
| Grants: | European Commission 952334 Agencia Estatal de Investigación PID2019-105017RB-I00 Ministerio de Ciencia e Innovación IJC2019-041039-I |
| Rights: | Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. |
| Language: | Anglès |
| Document: | Article ; recerca ; Versió publicada |
| Subject: | Parkinson's disease ; Aggregation ; α-Synuclein ; Amyloid ; Inhibitor |
| Published in: | Pharmaceutics, Vol. 15, Issue 3 (March 2023) , art. 839, ISSN 1999-4923 |
34 p, 4.0 MB |